申请人:NANOGEN PHARMACEUTICAL BIOTECHNOLOGY
公开号:US20130230490A1
公开(公告)日:2013-09-05
The present application discloses new PEG-interferon lambda 1 conjugates (PEG-IFNλ1), processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same. These conjugates have increased blood half-lives and persistence time compared to IFNλ1 and are effective in the treatment of hepatitis B and hepatitis C.